Journal Articles

  1. et. al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes*. Science Translational Medicine 9(402), eaaf7779
  2. & Comparison of a point-of-care analyser for the determination of HbA1c with HPLC method. Practical Laboratory Medicine 8, 26-29.
  3. & Stability of proinsulin in whole blood. Clinical Biochemistry
  4. & Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System. Journal of Diabetes Science and Technology 10(5), 1195-1196.
  5. & Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33(11), 1564-1568.
  6. & Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function. The Journal of Clinical Endocrinology & Metabolism 101(2), 572-580.
  7. & Association between the preoperative fasting and postprandial C-peptide AUC with resolution of type 2 diabetes 6months following bariatric surgery. Metabolism 64(11), 1556-1563.
  8. & Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis. Journal of Diabetes Research 2015, 1-8.
  9. & Similar magnitude of post-exercise hyperglycemia despite manipulating resistance exercise intensity in type 1 diabetes individuals. Scandinavian Journal of Medicine & Science in Sports, n/a-n/a.
  10. & Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus. Clinica Chimica Acta 447, 90-95.
  11. et. al. Impact of single and multiple sets of resistance exercise in type 1 diabetes. Scandinavian Journal of Medicine & Science in Sports, n/a-n/a.
  12. et. al. Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in Type 1 diabetes. Diabetic Medicine 31(8), 1009-1013.
  13. et. al. Metabolic Implications when Employing Heavy Pre- and Post-Exercise Rapid-Acting Insulin Reductions to Prevent Hypoglycaemia in Type 1 Diabetes Patients: A Randomised Clinical Trial. PLoS ONE 9(5), e97143
  14. et. al. Comparison of IFCC-calibrated HbA1c from laboratory and point of care testing systems. Diabetes Research and Clinical Practice 105(3), 364-372.
  15. et. al. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Human Reproduction 29(9), 2041-2049.
  16. & Comparison of daytime 12-hour metabolic profiles after treatment with repaglinide and gliclazide in type 2 diabetes. Practical Diabetes 30(1), 27-32.
  17. & Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes. Diabetes & Metabolism 39(4), 337-342.
  18. & A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes. Diabetes & Metabolism 39(6), 537-542.
  19. & Effects of lifestyle advice in people newly diagnosed with type 2 diabetes. Diabetes and Primary Care 13(5), 276-283.
  20. & Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 94(2), 199-206.
  21. & Experience of the introduction of routine antibody testing in primary care and of running a trial for latent autoimmune diabetes in adults (LADA). Diabetes Research and Clinical Practice 93(1), e49-e52.
  22. & The effect of a supported exercise programme in patients with newly diagnosed Type 2 diabetes: A pilot study. Journal of Sports Sciences 29(6), 579-586.
  23. & Impending Hyperglycemia in Normoglycemic Renal Transplant Recipients—An Experimental Predictive Surrogate. Transplantation 89(11), 1341-1346.
  24. & Daytime variability of postprandial glucose tolerance and pancreatic B-cell function using 12-h profiles in persons with Type 2 diabetes. Diabetic Medicine 27(3), 266-273.
  25. & Insulin Resistance Indexes in Renal Transplant Recipients Maintained on Tacrolimus Immunosuppression. Transplantation 89(3), 327-333.
  26. & Comparison of Rival Metabolic Syndrome Classifications Against Pathophysiological Markers in Renal Transplant Recipients. Transplantation 89(3), 347-352.
  27. & The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism 12(1), 82-87.
  28. & Insulin Hyposecretion in Nondiabetic, Tacrolimus-Treated Renal Transplant Recipients More Than 6 months Posttransplantation. Transplantation 87(12), 1870-1876.
  29. & Use of cystatin C-based estimations of glomerular filtration rate in patients with type 2 diabetes. Diabetologia 52(7), 1274-1278.
  30. & The Effect of Rosuvastatin on Insulin Sensitivity and Pancreatic Beta-Cell Function in Nondiabetic Renal Transplant Recipients. American Journal of Transplantation 9(6), 1439-1445.
  31. & Metformin Reduces Arterial Stiffness and Improves Endothelial Function in Young Women with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled, Crossover Trial. Journal of Clinical Endocrinology & Metabolism 95(2), 722-730.
  32. & Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1cin subjects with Type 2 diabetes. Diabetic Medicine 26(10), 974-980.
  33. & Performance of the revised ‘175’ Modification of Diet in Renal Disease equation in patients with type 2 diabetes. Diabetologia 51(9), 1714-1718.
  34. & Influence of Body Weight on the Performance of Glomerular Filtration Rate Estimators in Subjects With Type 2 Diabetes. Diabetes Care 31(1), 47-49.